PEB
11/11/2015 09:46
KEYDATES
NOT PRICE SENSITIVE
REL: 0946 HRS Pacific Edge Limited
KEYDATES: PEB: Interim Results to be released on 26 November 2015
11 November 2015
INTERIM RESULTS TO BE RELEASED ON 26 NOVEMBER 2015
Pacific Edge Limited (NZX:PEB) intends to announce its interim results for
the half year ended 30 September 2015 (HY16) on Thursday 26 November 2015,
prior to 10am NZDT.
This will be followed by an analyst and investor conference call to review
the HY16 results and the company's outlook for the remainder of the 2016
financial year.
The conference call is scheduled to begin at 10.30am NZDT. To attend the
conference call, participants will need to dial into one of the numbers below
at least 5-10 minutes prior to the scheduled call time and identify yourself
to the operator. When prompted, please quote the confirmation code: 1922263.
An archive of the conference call will be made available within 48 hours in
the Investor section on the Pacific Edge website.
If you have any queries regarding the results announcement or the conference
call, please contact Tana-Lee Henare on 03 479 5806 or
[email protected].
Dial toll free from NZ: 0800 450 585
Dial toll free from Australia: 1800 554 798
Dial toll free from Singapore: 800 6163 105
Dial toll free from Hong Kong 800 901 587
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
GENERAL OVERVIEW
www.pacificedge.co.nz
www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and monitoring of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies.
PRODUCTS
Pacific Edge has two proprietary, novel, accurate, molecular diagnostic
products in-market providing more accurate, and better detection and
management of urothelial cancer. Cxbladder Detect is available through the
company's dedicated CLIA certified laboratories for customers in New Zealand,
Australia and the USA. Cxbladder Triage is available in New Zealand and
Australia and will launch in the USA in 2015.
ABOUT Cxbladder Triage
www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with extra
phenotypic and clinical risk factors to accurately identify and remove
patients with haematuria who have a low probability of bladder cancer, from
requiring a full-urological work-up. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation and is intended to reduce of
the number of patients needing an expensive and invasive work-up for
urothelial cancer.
ABOUT Cxbladder Detect
www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.
Refer to www.cxbladder.com for more information.
End CA:00273186 For:PEB Type:KEYDATES Time:2015-11-11 09:46:45
